A carregar...
The Three P’s: Parotid, PD-L1, and Pembrolizumab
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Limited
2019-01-01
|
| Colecção: | Case Reports in Oncological Medicine |
| Acesso em linha: | http://dx.doi.org/10.1155/2019/2305315 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|